ClinicalTrials.gg
CompletedNCT01817764Updated Nov 8, 2017Results posted

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Umeclidinium/vilanterol and Fluticasone propionate/salmeterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 59 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-11-08.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
707
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.

Enrollment
10th of 43
707 · median 131
Started
2013
with 2 others
Phase 3
14 of 43
none open now
Registered
21st of 43
by date
Lead sponsor
35 of 43
GlaxoSmithKline

Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 10th largest by enrollment, is one of 3 that started in 2013, is one of 14 in phase 3, and was the 21st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About GSK573719

GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC) in subjects with COPD. Subjects who meet the eligibility criteria at Screening will complete a 7 to 14 day Run-in period. At the end of the run-in period, approximately 710 eligible subjects will be equally randomized (to complete at least 568 evaluable subjects) to one of the 2 treatment groups for 12 weeks: 1. UMEC/VI 62.5/25 micrograms (mcg) administered as one inhalation once-daily in the morning via the Novel dry powder inhaler (NDPI) + placebo administered as one inhalation each morning and evening via single multidose powdered inhaler (ACCUHALER/DISKUS) or 2. FSC 250/50 mcg administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once-daily in the morning via NDPI. A safety Follow-up assessment will be conducted approximately 7 days after the end of the study treatment (Early Withdrawal, if applicable). The total duration of subject participation will be approximately 15 weeks.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • umeclidinium bromide (UMEC)
  • vilanterol (VI)
  • salmeterol (SAL)
  • fluticasone propionate (FP)
  • Novel Dry Powder Inhaler (NDPI)
  • Chronic obstructive pulmonary disease
  • GW642444
  • GSK573719
  • lung function
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient
  • A signed and dated written prior to study participation
  • Male or female subjects, 40 years of age or older at Visit 1
  • A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is or surgically sterile). - A female is eligible to enter and participate in the study if she is of: Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable methods as listed in the protocol used consistently and correctly.
  • An established clinical history of in accordance with the definition by the American Thoracic Society/European Respiratory Society as follows: Chronic obstructive pulmonary disease is a preventable and treatable disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences
  • Smoking history: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years (number of pack years = [number of cigarettes per day/20] x number of years smoked [e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar use cannot be used to calculate pack year history
  • Severity of disease: A pre and post-salbutamol /Forced Vital Capacity (FVC) ratio of \<0.70 and a post-salbutamol FEV1 of >=30% and \<=70% of predicted normal values calculated using National Health and Nutrition Examination Survey (NHANES) III reference equations at Visit 1
  • Dyspnea: A score of >=2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit 1

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating or are planning on becoming pregnant during the study
  • A current diagnosis of asthma
  • Other Respiratory Disorders: Known α-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject, who, in the opinion of the investigator, has any other significant respiratory condition in addition to should be excluded. Examples may include bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease. Inactive tuberculosis in more than one lobe is exclusionary. Allergic rhinitis is not exclusionary
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \<5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study
  • : A history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, , lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic
  • Hospitalization for pneumonia within 12 weeks prior to Visit 1
  • History of COPD Exacerbation: A documented history of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics, and/or hospitalization. Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1)
  • 12-Lead (ECG): An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility.
  • Medication Prior to Spirometry: Unable to withhold salbutamol for the 4 hour period required prior to spirometry testing at each study visit
  • Medications Prior to Screening: Use of the following medications according to the following defined time intervals prior to Visit 1: Depot corticosteroids - 12 weeks, Systemic, oral or parenteral corticosteroids - 6 weeks, Antibiotics (for lower respiratory tract infection) - 6 weeks, Cytochrome P450 3A4 strong inhibitors - 6 weeks, Herbal medications potentially containing oral or systemic steroids - 6 weeks, Inhaled corticosteroids (ICS) - 30 days, Long-acting beta2-agonist (LABA)/ICS combination products - 30 days, Phosphodiesterase 4 (PDE4) inhibitors (e.g., roflumilast) - 14 days, Inhaled long-acting anticholinergics - 7 days, Theophyllines - 48 hours, Oral leukotriene inhibitors (zafirlukast, montelukast, zileuton) - 48 hours, Oral beta2-agonists Long-acting-48 hours/Short-acting - 12 hours, Inhaled long acting beta2-agonists (LABA, e.g., salmeterol, formoterol, indacaterol) - 48 hours, Inhaled sodium cromoglycate or nedocromil sodium - 24 hours, Inhaled short acting beta2-agonists - 4 hours, Inhaled short-acting anticholinergics - 4 hours, Inhaled short-acting anticholinergic/short-acting beta2-agonist combination products - 4 hours, Any other medication - 30 days or within 5 drug half-lives (whichever is longer)
  • Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., \<=12 hours per day) is not exclusionary
  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., salbutamol) via nebulized therapy.
  • Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded
  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1
  • Affiliation with Investigator Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator
  • Inability to read: A subject will not be eligible for the study if in the opinion of the investigator the subject cannot read
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
707 participants (actual)

Study arms

  • Experimental
    Umeclidinium/vilanterol Arm

    The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via the NDPI and placebo administered as one inhalation each morning and evening via ACCUHALER/DISKUS

    Drug: Umeclidinium/vilanterol · Drug: Placebo

  • Active comparator
    Fluticasone propionate/salmeterol Arm

    The subjects will receive FSC 250/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS and placebo administered once-daily in the morning via NDPI

    Drug: Fluticasone propionate/salmeterol · Drug: Placebo

Interventions

  • DrugUmeclidinium/vilanterol

    Drug pages: GSK573719 · Vilanterol

    Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning

  • DrugFluticasone propionate/salmeterol

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening

  • DrugPlacebo

    Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 24-hour Weighted-mean Serial FEV1 on Treatment Day 84

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5 and 15 minutes and 1, 3, 6, 9, 12 (pre-evening dose), 13, 15, 18, 23, and 24 hours after the morning dose. Change from Baseline was calculated as the value at Day 84 minus the value at Baseline. Analysis was performed using an analysis of covariance of treatment, Baseline (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), and smoking status. par.=participants.

    Time frame: Baseline and Day 84

Secondary outcomes

  1. Change From Baseline in Trough FEV1 on Day 85

    Trough FEV1 on Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after morning dosing/11 and 12 hours after evening dosing on Day 84. Change from Baseline is calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, day, and day by Baseline and day by treatment interactions.

    Time frame: Baseline and Day 85

07

Results

Posted May 29, 2014

Participant flow

Participant flow — Overall Study
MilestoneUMEC/VI 62.5/25 µg QDFSC 250/50 µg BID
Started353353
Completed319315
Not completed3438
Withdrew: Adverse event710
Withdrew: Lack of efficacy97
Withdrew: Protocol violation75
Withdrew: Lost to follow-up14
Withdrew: Withdrawal by subject1012

Outcome measures

PrimaryChange From Baseline in 24-hour Weighted-mean Serial FEV1 on Treatment Day 84

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5 and 15 minutes and 1, 3, 6, 9, 12 (pre-evening dose), 13, 15, 18, 23, and 24 hours after the morning dose. Change from Baseline was calculated as the value at Day 84 minus the value at Baseline. Analysis was performed using an analysis of covariance of treatment, Baseline (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), and smoking status. par.=participants.

Time frame:
Baseline and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline in 24-hour Weighted-mean Serial FEV1 on Treatment Day 84
LitersUMEC/VI 62.5/25 µg QDFSC 250/50 µg BID
Change From Baseline in 24-hour Weighted-mean Serial FEV1 on Treatment Day 840.165 ± 0.01300.091 ± 0.0131
Statistical analysis
  • UMEC/VI 62.5/25 µg QD vs FSC 250/50 µg BID · ANCOVA · p = <0.001 · Mean difference (net): 0.074 · 95% CI 0.038 to 0.110
SecondaryChange From Baseline in Trough FEV1 on Day 85

Trough FEV1 on Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after morning dosing/11 and 12 hours after evening dosing on Day 84. Change from Baseline is calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, day, and day by Baseline and day by treatment interactions.

Time frame:
Baseline and Day 85
Reported as:
Least squares mean · Liters
Change From Baseline in Trough FEV1 on Day 85
LitersUMEC/VI 62.5/25 µg QDFSC 250/50 µg BID
Change From Baseline in Trough FEV1 on Day 850.154 ± 0.01330.072 ± 0.0134

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the follow-up contact (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UMEC/VI 62.5/25 µg QD—6/353 (1.7%)38/353 (10.8%)
FSC 250/50 µg BID—10/353 (2.8%)25/353 (7.1%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventUMEC/VI 62.5/25 µg QDFSC 250/50 µg BID
PneumoniaInfections and infestations0/3533/353
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/3533/353
Ischaemic strokeNervous system disorders0/3532/353
BronchitisInfections and infestations0/3531/353
Burn infectionInfections and infestations0/3531/353
Gastroenteritis viralInfections and infestations1/3530/353
Infective exacerbation of chronic obstructive airways diseasInfections and infestations0/3531/353
Obstructive airways disorderRespiratory, thoracic and mediastinal disorders1/3530/353
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/3531/353
Head injuryInjury, poisoning and procedural complications1/3530/353
Most frequent other events
Most frequent other events
EventUMEC/VI 62.5/25 µg QDFSC 250/50 µg BID
HeadacheNervous system disorders23/35317/353
NasopharyngitisInfections and infestations16/3538/353

Baseline characteristics

Age, Continuous
Age, Continuous(Years)UMEC/VI 62.5/25 µg QDFSC 250/50 µg BIDTotal
Mean62.5 ± 9.0563.0 ± 8.9162.8 ± 8.97
Sex: Female, Male
Sex: Female, Male(Participants)UMEC/VI 62.5/25 µg QDFSC 250/50 µg BIDTotal
Female100109209
Male253244497
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)UMEC/VI 62.5/25 µg QDFSC 250/50 µg BIDTotal
African American/African Heritage437
American Indian or Alaska Native5510
Asian - East Asian Heritage112
Asian - Japanese Heritage213
White - Arabic/North African Heritage011
White - White/Caucasian/European341342683
08

Study locations

59 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    Clearwater, Florida 33765-2616, United States
  • GSK Investigational Site
    Columbus, Ohio 43215, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1425AGC, Argentina
  • GSK Investigational Site
    Mar del Plata, Buenos Aires 7600, Argentina
  • GSK Investigational Site
    Buenos Aires, C1424BSF, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425FVH, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, 4000, Argentina
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500800, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8910131, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago, Chile
  • GSK Investigational Site
    Quillota, Valparaíso 2260000, Chile
  • GSK Investigational Site
    Valparaiso, Valparaíso 2341131, Chile
  • GSK Investigational Site
    Santiago, 8380453, Chile
  • GSK Investigational Site
    Santiago, 8910131, Chile
  • GSK Investigational Site
    Santiago, Chile
  • GSK Investigational Site
    Viña del Mar, 2570017, Chile
  • GSK Investigational Site
    Athens, 106 76, Greece
  • GSK Investigational Site
    Athens, 115 27, Greece
  • GSK Investigational Site
    Athens, 151 26, Greece
  • GSK Investigational Site
    Haidari / Athens, 124 62, Greece
  • GSK Investigational Site
    Heraklion, Crete, 71110, Greece
  • GSK Investigational Site
    Rethymnon, Crete, 74100, Greece
  • GSK Investigational Site
    Thessaloniki, 56429, Greece
  • GSK Investigational Site
    Thessaloniki, 57010, Greece
  • GSK Investigational Site
    Lima 27, Lima Lima 27, Peru
  • GSK Investigational Site
    Bacau, 600252, Romania
  • GSK Investigational Site
    Bucharest, 020125, Romania
  • GSK Investigational Site
    Bucharest, 050159, Romania
  • GSK Investigational Site
    Cluj-Napoca, 400371, Romania
  • GSK Investigational Site
    Iasi, 700115, Romania
  • GSK Investigational Site
    Ploiesti, 100184, Romania
  • GSK Investigational Site
    Ploiesti, 100379, Romania
  • GSK Investigational Site
    Ramnicu Valcea, 240564, Romania
  • GSK Investigational Site
    Suceava, 720284, Romania
  • GSK Investigational Site
    Timisoara, 300310, Romania
  • GSK Investigational Site
    Dnipropetrovsk, 49051, Ukraine
  • GSK Investigational Site
    Donetsk, 83003, Ukraine
  • GSK Investigational Site
    Donetsk, 83114, Ukraine
  • GSK Investigational Site
    Kharkiv, 61124, Ukraine
  • GSK Investigational Site
    Kiev, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 01114, Ukraine
  • GSK Investigational Site
    Kyiv, 02091, Ukraine
  • GSK Investigational Site
    Kyiv, 03049, Ukraine
  • GSK Investigational Site
    Kyiv, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 04201, Ukraine
  • GSK Investigational Site
    Poltava, 36024, Ukraine
  • GSK Investigational Site
    Vinnytsia, 21018, Ukraine
  • GSK Investigational Site
    Yalta, 98603, Ukraine
09

References and documents

Publications

  • Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015 Jul;109(7):870-81. doi: 10.1016/j.rmed.2015.04.018. Epub 2015 May 8. PubMed 26006754 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2013
First posted
Mar 25, 2013
Start
Mar 1, 2013
Primary completionActual
Oct 1, 2013
CompletionActual
Oct 25, 2013
Results first posted
May 29, 2014
Last update
Nov 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01817764
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 25, 2013
Start date
Mar 1, 2013
Primary completion
Oct 1, 2013
Completion
Oct 25, 2013
Results posted
May 29, 2014
Last update
Nov 8, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK573719 · Vilanterol

Start the discussion